Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses
Open Access
Abstract
Targeted therapy resistance frequently develops in melanoma due to intratumor heterogeneity and epigenetic reprogramming. This also typically induces cross-resistance to immunotherapies. Whether this includes additional modes of therapy has not been fully assessed. We show that co-treatments of MAPKi with VSV-based oncolytics do not function in a synergistic fashion; rather, the MAPKis block infection. Melanoma resistance to vemurafenib further perturbs the cells’ ability to be infected by oncolytic viruses. Resistance to vemurafenib can be induced by the loss of SOX10, a common proliferative marker in melanoma. The loss of SOX10 promotes a cross-resistant state by further inhibiting viral infection and replication. Analysis of RNA-seq datasets revealed an upregulation of interferon-stimulated genes (ISGs) in SOX10 knockout populations and targeted therapy-resistant cells. Interestingly, the induction of ISGs appears to be independent of type I IFN production. Overall, our data suggest that the pathway mediating oncolytic resistance is due to the loss of SOX10 during acquired drug resistance in melanoma.Keywords
Funding Information
- CIHR
- CCSRI
This publication has 38 references indexed in Scilit:
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory ActivityJournal of Investigative Dermatology, 2014
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanomaNature, 2014
- Interferon-Stimulated Genes: A Complex Web of Host DefensesAnnual Review of Immunology, 2014
- Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virusSurgery, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma ModelsCancer Research, 2010
- Viruses and interferon: a fight for supremacyNature Reviews Immunology, 2002